IDT Australia Ltd - Company Profile
Powered by 
All the sales intelligence you need on IDT Australia Ltd in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how IDT Australia Ltd fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with IDT Australia Ltd.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
IDT Australia Ltd (IDT Australia) specializes in high containment and high potency manufacturing of active pharmaceutical ingredients (APIs) and finished dose forms (FDF). The company focuses on advanced therapies, including mRNA, and antibody drug conjugates (ADCs), offering targeted treatments for complex diseases. The company excels in aseptic fill and finish services, providing tailored solutions for sterile products in cGMP-compliant environments. IDT manufactures medicinal cannabis and psychedelics, including S8 and S9 APIs. It also offers oral finished dose form development, API manufacturing, and support through all clinical trial phases, with expertise in high-potency and cytotoxic materials. IDT Australia is headquartered in Boronia, Victoria, Australia.
Headquarters
Australia
Address
45 Wadhurst Dr, Boronia, Melbourne, Victoria, 3155
Website
www.idtaus.com.au
Telephone
61 398018888
No of Employees
156
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
IDT (ASX)
Revenue (2025)
$13.1M
40.6%
(2025 vs 2024)
EPS
XYZ
Net Income (2025)
XYZ
-49%
(2025 vs 2024)
Market Cap*
$9.5M
Net Profit Margin (2025)
XYZ
-5.9%
(2025 vs 2024)
* As of and is in US$
IDT Australia Ltd premium industry data and analytics
Products and Services
| Products | Services |
|---|---|
| Active Pharmaceutical Ingredients and Intermediates | Aseptic Fill and Finish Services |
| Specialty Orals: | Contract Development and Manufacturing (CDMO) |
| Psychedelics and Medicinal Cannabis | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Contracts/Agreements | In November, the company was awarded a five-year contract by Nacuity Pharmaceuticals Pty Ltd, for the manufacture of NPI-001 tablets, an investigational treatment for retinitis pigmentosa. |
| 2025 | Corporate Changes/Expansions | In July, the company inaugurated its new facility, the Ehrlich Bioconjugation Center. |
| 2025 | Contracts/Agreements | In July, the company entered into an agreement with Gelteq Limited, to secure dedicated new product development and manufacturing facilities. |
Competitor Comparison
| Key Parameters | IDT Australia Ltd | Mayne Pharma Group Ltd | Starpharma Holdings Ltd | Bionomics Ltd | Catalent Inc |
|---|---|---|---|---|---|
| Headquarters | Australia | Australia | Australia | United States of America | United States of America |
| City | Melbourne | Adelaide | Melbourne | - | Somerset |
| State/Province | Victoria | South Australia | Victoria | - | New Jersey |
| No. of Employees | 156 | 450 | 50 | 8 | 16,900 |
| Entity Type | Public | Public | Public | Private | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Mark Simari | Chairman; Chief Executive Officer | Executive Board | 2025 | - |
| Jim Sosic | Chief Operating Officer | Senior Management | 2023 | - |
| Michael B. Thompson | Director - Commercial & Business Development | Senior Management | 2025 | - |
| Mark Licciardo | Secretary | Senior Management | 2022 | - |
| Priscilla Thiyageas | Quality Director | Senior Management | 2022 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer